Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants
- Conditions
- Respiratory Syncytial Virus
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- Janssen Sciences Ireland UC
- Registration Number
- NCT04221412
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 16
- Registration Number
- NCT04208399
- Locations
- 🇩🇪
APEX GmbH, Munchen, Germany
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 16
- Registration Number
- NCT04208386
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
Phase 2
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: Placebo for JNJ-73763989Drug: Placebo for JNJ-56136379
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 130
- Registration Number
- NCT04129554
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria di Modena, Ospedale di Baggiovara, Modena, Italy
🇬🇧Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧North Manchester General Hospital, Crumpsall, United Kingdom
Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)
Phase 2
Terminated
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: JNJ-53718678 250 mgDrug: PlaceboDrug: JNJ-53718678 125 mg
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 3
- Registration Number
- NCT04056611
- Locations
- 🇪🇸
Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain
🇪🇸Hosp. Gral. Univ. Gregorio Maranon, Madrid, Spain
🇪🇸Hosp. Univ. 12 de Octubre, Madrid, Spain
A Study of JNJ-73763989 in Healthy Japanese Adult Participants
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 25
- Registration Number
- NCT04002752
- Locations
- 🇬🇧
PAREXEL International, London, United Kingdom
A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
Phase 2
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: Placebo for JNJ-73763989Drug: Placebo for JNJ-56136379Drug: Nucleos(t)ide Analog (NA)
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 471
- Registration Number
- NCT03982186
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪Universitaetsklinikum Leipzig, Leipzig, Germany
🇩🇪Universitatsmedizin der Johannes Gutenberg Universitat Mainz, Mainz, Germany
A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 16
- Registration Number
- NCT03945539
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection
- Conditions
- HIV
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Janssen Sciences Ireland UC
- Registration Number
- NCT03847376
A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed
Phase 1
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Biological: PlaceboBiological: JNJ-64300535Drug: Nucleos(t)ide Analogs (NA)
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 30
- Registration Number
- NCT03463369
- Locations
- 🇧🇪
Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇩🇪UK Leipzig, Leipzig, Germany
🇬🇧Bart's Health - Blizard Inst. London, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath